Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heating the body to fight pancreatic cancer: a new trial tests Whole-Body hyperthermia

NCT ID NCT07711067

Not yet recruiting Disease control Sponsor: ElmediX Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study randomly assigns participants to receive either standard therapy alone or standard therapy plus whole-body hyperthermia sessions. The main goal is to see if the combination extends overall survival while remaining safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
whole-body hyperthermia (a device that raises body temperature to 41.5°C for 4 hours) plus standard-of-care systemic therapy
What this could lead to
If it works, this could offer a new treatment option for people with metastatic pancreatic cancer who have run out of standard options.
What could go wrong
This is a mid-stage trial with only 95 participants, so results may not be conclusive. The treatment involves raising body temperature to a very high level, which carries risks like heat-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyperthermia pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Algemeen Ziekenhuis Maria Middelares (AZ MM)

    Ghent, Oost-Vlaanderen, 9000, Belgium

    Contact

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

    Contact

  • Hospital Universitario HM Sanchinarro (HM CIOCC)

    Madrid, Madrid, 28050, Spain

    Contact

  • Universitair Ziekenhuis Antwerpen (UZA)

    Antwerp, Antwerpen, 2650, Belgium

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.